breast-cancer-2017-keynote

2 / 3

Page 10
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 3
Breast Cancer November 01-02, 2017 | Toronto, Canada
7th World Congress on
During the last several years, increased public awareness,
advances in breast imaging and enhanced screening
programs have led to early breast cancer detection and
attention to cancer prevention. The numbers of image-
detected biopsies have increased and pathologists are
expected to provide more information with smaller tissue
samples. These biopsies have resulted in detection of
increasing numbers of high-risk proliferative breast disease
and in situ cancers. The general hypothesis is that some forms
of breast cancers may arise from established forms of ductal
carcinoma in situ (DCIS) and atypical ductal hyperplasia
(ADH) and possibly from more common forms of ductal
hyperplasia. However, this is an oversimplification of a very
complex process, given the fact that the majority of breast
cancers appears to arise de-novo or from a yet unknown
precursor lesion. Currently, ADH and DCIS are considered
as morphologic risk factors and precursor lesions for breast
cancer. However, morphologic distinction between these two
entities has remained a real issue that continues to lead to
over diagnosis and overtreatment. Aside from morphologic
similarities between ADH and low grade DCIS, biomarker
studies and molecular genetic testing’s have shown that
morphologic overlaps are reflected at the molecular levels
and raise questions about the validity of separating these
two entities. It is hoped that as we better understand the
genetic basis of these entities in relation to ultimate patient
outcome, the suggested use of the term of borderline breast
disease can minimize the number of patients who are subject
to overtreatment.
Speaker Biography
Shahla Masood is a Persian-born physician, who currently holds the positions of
Professor and Chair of the Department of Pathology at University of Florida College of
Medicine. She is the founder and Editor-in-Chief of The Breast Journal, the founder and
past president of the “International Society of Breast Pathology,” the Director of the
“Annual Multidisciplinary Symposium on Breast Disease”, “The Breast Cancer Public
Forum”, and is currently the President of “The World Society for Breast Health.” She
has been named as one of the Top Doctors in America and one of the 20 Top Professors
in Oncology at an international level. Dr. Masood is a patient advocate, a partner in
community affairs and an accomplished artist and gourmet chef.
e:
Shahla Masood
University of Florida College of Medicine, USA
Pathology of premalignant breast disease